GEN Exclusives

More »

GEN News Highlights

More »
Dec 4, 2006

Merck will Evaluate Neuroptix’ Laser Eye Scanning Alzheimer's Diagnostics

  • Merck & Co. will evaluate Neuroptix' Alzheimer’s diagnostic tool in preclinical models of the disease and clinical trial monitoring of potential new drugs. The Neuroptix™ QEL laser eye scanning device detected Alzheimer's-related amyloid protein aggregates in the lens of the eye in preclinical studies in mice. The amyloid protein aggregates are a surrogate biomarker of beta amyloid in the brain.

    "Our goal is to help bring the QEL system closer to becoming a fast, inexpensive, and reliable screening test for Alzheimer's that can be easily administered in a general practitioner's office with accurate results,” says Paul Hartung, president and CEO of Neuroptix.

    Under the agreement, Neuroptix will receive an upfront payment, annual technology access fees, and milestone payments. Neuroptix will also receive payments for instruments, diagnostic agents, and services. Merck receives a nonexclusive license to use Neuroptix' technology for preclinical and clinical research purposes.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »